Cardiomyopathy epidemiology and demographics

Revision as of 15:09, 6 January 2019 by Mmir (talk | contribs) (→‎References)
Jump to navigation Jump to search

Cardiomyopathy Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Cardiomyopathy from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Guidelines

2023 ESC Guideline Recommendations

2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy

Case Studies

Case #1

Cardiomyopathy epidemiology and demographics On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Cardiomyopathy epidemiology and demographics

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Cardiomyopathy epidemiology and demographics

CDC on Cardiomyopathy epidemiology and demographics

Cardiomyopathy epidemiology and demographics in the news

Blogs on Cardiomyopathy epidemiology and demographics

Directions to Hospitals Treating Cardiomyopathy

Risk calculators and risk factors for Cardiomyopathy epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Incidence and prevalence differ based on cause. The incidence of DCM has been estimated to be 5-8 cases per 100,000 population, with a prevalence of 36 per 100,000. This could be explained by the incomplete disease expression, which goes unrecognized. The prevalence of HCM in the absence of aortic valve disease or systemic hypertension is at least 200 per 100,000 of the adult population. RCM is much less common than either DCM or HCM in the developed world, but is a frequent cause of death in the tropical countries, primarily because of the high incidence of endomyocardial fibrosis in those regions.

Cardiomyopathy Epidemiology and Demographics

Incidence and prevalence differ based on cause.[1]

  • The incidence of DCM has been estimated to be 5-8 cases per 100,000 population, with a prevalence of 36 per 100,000. This could be explained by the incomplete disease expression, which goes unrecognized.[2]
  • The prevalence of HCM in the absence of aortic valve disease or systemic hypertension is at least 200 per 100,000 of the adult population.[3]
  • RCM is much less common than either DCM or HCM in the developed world, but is a frequent cause of death in the tropical countries, primarily because of the high incidence of endomyocardial fibrosis in those regions.[4]
  • African–American individuals are approximately three times more prone to development of dilated cardiomyopathy.
  • Hypertrophic cardiomyopathy has a prevalence of 400-800 per 100,0000 in adults. This prevalence seems to be similar in all races, but the disease age is mainly considered to be in adolescence and you adults.[4]
  • Dilated cardiomyopathy has an approximate incidence of 4.58 per 100,000 in children less than 1 year old. The incidence decrease when the child ages and is 0.34 per 100,000 between 1 to 18 years old. [4]
  • The incidence of dilated cardiomyopathy was estimated to be 400-800 cases per 100,000 individuals worldwide.[5]

References

  1. Richard P, Charron P, Carrier L, Ledeuil C, Cheav T, Pichereau C, Benaiche A, Isnard R, Dubourg O, Burban M, Gueffet JP, Millaire A, Desnos M, Schwartz K, Hainque B, Komajda M (May 2003). "Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy". Circulation. 107 (17): 2227–32. doi:10.1161/01.CIR.0000066323.15244.54. PMID 12707239.
  2. Kushwaha SS, Fallon JT, Fuster V (January 1997). "Restrictive cardiomyopathy". N. Engl. J. Med. 336 (4): 267–76. doi:10.1056/NEJM199701233360407. PMID 8995091.
  3. Kawasaki K, Miyaji K, Kodera S, Suzuki Y, Kanda J, Ikeda M (May 2015). "Arrhythmogenic right ventricular cardiomyopathy in a patient with schizophrenia". Clin Case Rep. 3 (5): 308–14. doi:10.1002/ccr3.230. PMID 25984311.
  4. 4.0 4.1 4.2 Maron BJ, Gardin JM, Flack JM, Gidding SS, Kurosaki TT, Bild DE (August 1995). "Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults". Circulation. 92 (4): 785–9. PMID 7641357.
  5. Lipshultz SE, Sleeper LA, Towbin JA, Lowe AM, Orav EJ, Cox GF, Lurie PR, McCoy KL, McDonald MA, Messere JE, Colan SD (April 2003). "The incidence of pediatric cardiomyopathy in two regions of the United States". N. Engl. J. Med. 348 (17): 1647–55. doi:10.1056/NEJMoa021715. PMID 12711739.